Advertisement

Hematology and Oncology in Critical Illness

  • Leonardo R. Brandão
  • Scott C. Howard
  • Kenneth W. Gow
  • Surender Rajasekaran
  • Robert F. Tamburro
Chapter

Abstract

This chapter will focus on a variety of hematologic issues pertinent to the care of critically ill children. This is an area of intense research with the pathophysiology underlying these clinical conditions becoming progressively better understood. This improved understanding has resulted in new therapeutic strategies that are being assessed in multicenter clinical trials. The chapter will begin by describing the incidence and pathophysiologic significance of anemia in the pediatric intensive care unit (PICU) providing a differential diagnosis of the many conditions that may present with anemia in this setting. The chapter will next consider disseminated intravascular coagulation (DIC) focusing on the pathophysiology of a condition that has been associated with much morbidity and mortality. The underlying conditions predisposing to DIC will be detailed as well as a number of treatment options that have been implemented in clinical trials. In addition to DIC, thrombocytopenia may be caused by a number of other clinical conditions important to the pediatric critical care provider. The clinical and prognostic significance of thrombocytopenia will be addressed and a focused differential diagnosis will be provided. Thrombotic disorders are becoming increasingly recognized in children and are a particular concern for the pediatric intensivist. The epidemiology of thromboembolism in children will be reviewed focusing on the conditions most commonly associated with these thromboses. Finally, a chapter on hematologic issues in the critically ill child would not be complete without a discussion of sickle cell disease. Acute chest syndrome, one of the most frequent complications of sickle cell disease resulting in the need for intensive care services, will be discussed in detail.

Keywords

Hematopoietic Stem Cell Transplantation Sickle Cell Disease Pediatric Intensive Care Unit Disseminate Intravascular Coagulation Hemolytic Uremic Syndrome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Suggested Readings

  1. Abraham E, Reinhart K, Opal S, OPTIMIST Trial Study Group, et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA. 2003;290:238–47.PubMedCrossRefGoogle Scholar
  2. Andrew M, David M, Adams M, et al. Venous thromboembolic complications (VTE) in children: first analyses of the Canadian Registry of VTE. Blood. 1994;83:1251–7.PubMedGoogle Scholar
  3. Anghelescu DL, Burgoyne LL, Liu T, et al. Clinical and diagnostic imaging findings predict anesthetic complications in children presenting with malignant mediastinal masses. Paediatr Anaesth. 2007;17:1090–8.PubMedGoogle Scholar
  4. Bateman ST, Lacroix J, Boven K, Pediatric Acute Lung Injury and Sepsis Investigators Network, et al. Anemia, blood loss, and blood transfusions in North American children in the intensive care unit. Am J Respir Crit Care Med. 2008;178:26–33.PubMedCrossRefGoogle Scholar
  5. Bernard GR, Vincent JL, Laterre PF, Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001;344:699–709.PubMedCrossRefGoogle Scholar
  6. Borenstein SH, Gerstle T, Malkin D, Thorner P, Filler RM. The effects of prebiopsy corticosteroid treatment on the diagnosis of mediastinal lymphoma. J Pediatr Surg. 2000;35:973–6.PubMedCrossRefGoogle Scholar
  7. British Committee for Standards in Haematology General Haematology Task Force. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol. 2003;120:574–96.CrossRefGoogle Scholar
  8. Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol. 2004;127:3–11.PubMedCrossRefGoogle Scholar
  9. Cairo MS, Coiffier B, Reiter A, Younes A. TLS expert panel. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br J Haematol. 2010;149:578–86.PubMedCrossRefGoogle Scholar
  10. Coiffier B, Altman A, Pui CH, Younes A, Cairo MS. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol. 2008;26:2767–78.PubMedCrossRefGoogle Scholar
  11. Cuker A, Arepally G, Crowther MA, et al. The HIT Expert Probability (HEP) Score: a novel pre-test probability model for ­heparin-induced thrombocytopenia based on broad expert opinion. J Thromb Haemost. 2010;8:2642–50.PubMedCrossRefGoogle Scholar
  12. Dallman PR. Blood-forming tissues. In: Rudolph A, editor. Pediatrics. 16th ed. New York: Appleton; 1977. p. 1111.Google Scholar
  13. Davidson MB, Thakkar S, Hix JK, Bhandarkar ND, Wong A, Schreiber MJ. Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome. Am J Med. 2004;116:546–54.PubMedCrossRefGoogle Scholar
  14. Dhaliwal G, Cornett PA, Tierney Jr LM. Hemolytic anemia. Am Fam Physician. 2004;69:2599–606.PubMedGoogle Scholar
  15. Drews RE, Weinberger SE. Thrombocytopenic disorders in critically ill patients. Am J Respir Crit Care Med. 2000;162:347–51.PubMedGoogle Scholar
  16. Erslev AJ. Chapter 40. Clinical manifestations and classification of erythrocyte disorders. In: Beutler E, Lichtman MA, Coller BS, Kipps TJ, editors. Williams Hematology. 5th ed. New York: McGraw-Hill; 1995. p. 443.Google Scholar
  17. Esmon CT, Xu J, Lupu F. Innate immunity and coagulation. J Thromb Haemost. 2011;9 Suppl 1:182–8.PubMedCrossRefGoogle Scholar
  18. Fink MP. Pathophysiology of intensive care unit-acquired anemia. Crit Care. 2004;8:S9–10.PubMedCrossRefGoogle Scholar
  19. Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood. 2003;102:783–8.PubMedCrossRefGoogle Scholar
  20. Geaghan SM. Normal blood values: selected reference values for neonatal, pediatric, and adult populations. In: Hoffman R, Benz EJ, Shattil SJ, et al., editors. Hematology: basic principles and practice. 4th ed. Philadelphia: Elsevier; 2005. Appendix, p. 2733.Google Scholar
  21. George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood. 1996;88:3–40.PubMedGoogle Scholar
  22. George JN, Raskob GE, Shah SR, et al. Drug-induced thrombocytopenia: a systematic review of published case reports. Ann Intern Med. 1998;129:886–90.PubMedGoogle Scholar
  23. Goldman SC, Holcenberg JS, Finklestein JZ, et al. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood. 2001;97:2998–3003.PubMedCrossRefGoogle Scholar
  24. Goodman AM, Pollack MM, Patel KM, Luban NL. Pediatric red blood cell transfusions increase resource use. J Pediatr. 2003;142:123–7.PubMedCrossRefGoogle Scholar
  25. Hermiston ML, Mentzer WC. A practical approach to the evaluation of the anemic child. Pediatr Clin North Am. 2002;49:877–91.PubMedCrossRefGoogle Scholar
  26. Howard SC, Jones DP, Pui CH. The tumor lysis syndrome. N Engl J Med. 2011;364:1844–54.PubMedCrossRefGoogle Scholar
  27. Hsieh MM, Kang EM, Fitzhugh CD, et al. Allogeneic hematopoietic stem-cell transplantation for sickle cell disease. N Engl J Med. 2009;361:2309–17.PubMedCrossRefGoogle Scholar
  28. Hulbert ML, McKinstry RC, Lacey JL, et al. Silent cerebral infarcts occur despite regular blood transfusion therapy after first strokes in children with sickle cell disease. Blood. 2011;117:772–9.PubMedCrossRefGoogle Scholar
  29. Jilma-Stohlawetz P, Gilbert JC, Gorczyca ME, Knöbl P, Jilma B. A dose ranging phase I/II trial of the von Willebrand factor inhibiting aptamer ARC1779 in patients with congenital thrombotic thrombocytopenic purpura. Thromb Haemost. 2011;106:539–47.PubMedCrossRefGoogle Scholar
  30. Kaplan RN, Bussel JB. Differential diagnosis and management of thrombocytopenia in childhood. Pediatr Clin North Am. 2004;51:1109–40.PubMedCrossRefGoogle Scholar
  31. Khemani RG, Bart RD, Alonzo TA, Hatzakis G, Hallam D, Newth CJ. Disseminated intravascular coagulation score is associated with mortality for children with shock. Intensive Care Med. 2009;35:327–33.PubMedCrossRefGoogle Scholar
  32. Lacroix J, Hébert PC, Hutchison JS, TRIPICU Investigators, Canadian Critical Care Trials Group, Pediatric Acute Lung Injury and Sepsis Investigators Network, et al. Transfusion strategies for patients in pediatric intensive care units. N Engl J Med. 2007;356:1609–19.PubMedCrossRefGoogle Scholar
  33. Lapeyraque AL, Malina M, Fremeaux-Bacchi V, et al. Eculizumab in severe Shiga-toxin-associated HUS. New Engl J Med. 2011;364:2561–3.PubMedCrossRefGoogle Scholar
  34. Levi M. Current understanding of disseminated intravascular coagulation. Br J Haematol. 2004;124:567–76.PubMedCrossRefGoogle Scholar
  35. Levi M, ten Cate H. Disseminated intravascular coagulation. N Engl J Med. 1999;341:586–92.Google Scholar
  36. Levi M, de Jonge E, van der Poll T. New treatment strategies for disseminated intravascular coagulation based on current understanding of the pathophysiology. Ann Med. 2004;36:41–9.PubMedCrossRefGoogle Scholar
  37. Lo GK, Juhl D, Warkentin TE, Sigouin CS, Eichler P, Greinacher A. Evaluation of pretest clinical score (4 T’s) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost. 2006;4:759–65.PubMedCrossRefGoogle Scholar
  38. Manci EA, Culberson DE, Yang YM, et al. Causes of death in sickle cell disease: an autopsy study. Br J Haematol. 2003;123:359–65.PubMedCrossRefGoogle Scholar
  39. Marks PW, Glader B. Chapter 29. Approach to anemia in the adult and child. In: Hoffman R, Benz EJ, Shattil SJ, et al., editors. Hematology: basic principles and practice. 4th ed. Philadelphia: Elsevier; 2005. p. 462.Google Scholar
  40. Miller ST, Sleeper LA, Pegelow CH, et al. Prediction of adverse outcomes in children with sickle cell disease. N Engl J Med. 2000;342:83–9.PubMedCrossRefGoogle Scholar
  41. Monagle P, Adams M, Mahoney M, et al. Outcome of pediatric thromboembolic disease: a report from the Canadian Childhood Thrombophilia Registry. Pediatr Res. 2000;47:763–6.PubMedCrossRefGoogle Scholar
  42. Montesinos P, Lorenzo I, Martin G, et al. Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model. Haematologica. 2008;93:67–74.PubMedCrossRefGoogle Scholar
  43. Nowak-Gottl U, Auberger K, Gobel U, et al. Inherited defects of the protein C anticoagulant system in childhood thrombo-embolism. Eur J Pediatr. 1996;155:921–7.CrossRefGoogle Scholar
  44. Nowak-Gottl U, Kosch A, Schlegel N. Thromboembolism in newborns, infants and children. Thromb Haemost. 2001;86:464–74.PubMedGoogle Scholar
  45. Oski FA, Brugnara C, Nathan DG. A diagnostic approach to the anemic patient. In: Nathan G, Orkin SH, editors. Nathan and Oski’s hematology of infancy and childhood. 5th ed. Philadelphia: Saunders; 1998. p. 376.Google Scholar
  46. Perger L, Lee EY, Shamberger RC. Management of children and adolescents with a critical airway due to compression by an anterior mediastinal mass. J Pediatr Surg. 2008;43:1990–7.PubMedCrossRefGoogle Scholar
  47. Pession A, Barbieri E, Santoro N, Paolucci P, Porta F, Locatelli F. Efficacy and safety of recombinant urate oxidase (rasburicase) for treatment and prophylaxis of hyperuricemia in children undergoing chemotherapy. Haematologica. 2005;90:141–2.PubMedGoogle Scholar
  48. Powars DR. Management of cerebral vasculopathy in children with sickle cell anaemia. Br J Haematol. 2000;108:666–78.PubMedCrossRefGoogle Scholar
  49. Raffini L, Huang YS, Witmer C, Feudtner C. Dramatic increase in venous thromboembolism in children’s hospitals in the United States from 2001 to 2007. Pediatrics. 2009;124:1001–8.PubMedCrossRefGoogle Scholar
  50. Revel-Vilk S, Chan A, Bauman M, Massicotte P. Prothrombotic conditions in an unselected cohort of children with venous thromboembolic disease. J Thromb Haemost. 2003;1:915–21.PubMedCrossRefGoogle Scholar
  51. Richardson MW, Allen GA, Monahan PE. Thrombosis in children: current perspective and distinct challenges. Thromb Haemost. 2002;88:900–11.PubMedGoogle Scholar
  52. Schmugge M, Risch L, Huber AR, Benn A, Fischer JE. Heparin-induced thrombocytopenia-associated thrombosis in pediatric intensive care patients. Pediatrics. 2002;109:E10.PubMedCrossRefGoogle Scholar
  53. Shamberger RC, Holzman RS, Griscom NT, Tarbell NJ, Weinstein HJ, Wohl ME. Prospective evaluation by computed tomography and pulmonary function tests of children with mediastinal masses. Surgery. 1995;118:468–71.CrossRefGoogle Scholar
  54. Stein PD, Kayali F, Olson RE. Incidence of venous thromboembolism in infants and children: data from the National Hospital Discharge Survey. J Pediatr. 2004;145:563–5.PubMedCrossRefGoogle Scholar
  55. Steinberg MH. Management of sickle cell disease. N Engl J Med. 1999;340:1021–30.PubMedCrossRefGoogle Scholar
  56. Streif W, Andrew ME. Venous thromboembolic events in pediatric patients. Diagnosis and management. Hematol Oncol Clin North Am. 1998;12:1283–312.PubMedCrossRefGoogle Scholar
  57. Stricker PA, Gurnaney HG, Litman RS. Anesthetic management of children with an anterior mediastinal mass. J Clin Anesth. 2010;22:159–63.PubMedCrossRefGoogle Scholar
  58. Stuart MJ, Nagel RL. Sickle-cell disease. Lancet. 2004;364:1343–60.PubMedCrossRefGoogle Scholar
  59. Taylor Jr FB, Toh CH, Hoots WK, Wada H, Levi M, Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH). Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 2001;86:1327–30.PubMedGoogle Scholar
  60. van Ommen CH, Heijboer H, van den Dool EJ, Hutten BA, Peters M. Pediatric venous thromboembolic disease in one single center: congenital prothrombotic disorders and the clinical outcome. J Thromb Haemost. 2003;1:2516–22.PubMedCrossRefGoogle Scholar
  61. Vermylen C. Hematopoietic stem cell transplantation in sickle cell disease. Blood Rev. 2003;17:163–6.PubMedCrossRefGoogle Scholar
  62. Vichinsky EP. Pulmonary hypertension in sickle cell disease. N Engl J Med. 2004;350:857–9.PubMedCrossRefGoogle Scholar
  63. Vichinsky EP, Neumayr LD, Earles AN, et al. Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group. N Engl J Med. 2000;342:1855–65.PubMedCrossRefGoogle Scholar
  64. Walters MC, Storb R, Patience M, et al. Impact of bone marrow transplantation for symptomatic sickle cell disease: an interim report. Multicenter investigation of bone marrow transplantation for sickle cell disease. Blood. 2000;95:1918–24.PubMedGoogle Scholar
  65. Wang WC, Ware RE, Miller ST, et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet. 2011;377:1663–72.PubMedCrossRefGoogle Scholar
  66. Warkentin TE. An overview of the heparin-induced thrombocytopenia syndrome. Semin Thromb Hemost. 2004;30:273–83.PubMedCrossRefGoogle Scholar
  67. Warren BL, Eid A, Singer P, KyberSept Trial Study Group, et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA. 2001;286:1869–78.PubMedCrossRefGoogle Scholar
  68. Young G, Albisetti M, Bonduel M, et al. Impact of inherited thrombophilia on venous thromboembolism in children: a systematic review and meta-analysis of observational studies. Circulation. 2008;118:1373–82.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London Limited 2012

Authors and Affiliations

  • Leonardo R. Brandão
    • 1
  • Scott C. Howard
    • 2
  • Kenneth W. Gow
    • 3
  • Surender Rajasekaran
    • 4
  • Robert F. Tamburro
    • 5
  1. 1.Hematology/Oncology, Department of PediatricsUniversity of Toronto, The Hospital for Sick ChildrenTorontoCanada
  2. 2.Leukemia/Lymphoma, Department of OncologyUniversity of Tennessee, St. Jude Children’s Research HospitalMemphisUSA
  3. 3.Pediatric General and Thoracic Surgery, Department of SurgeryUniversity of Washington, Seattle Children’s HospitalSeattleUSA
  4. 4.Pediatric Critical Care Medicine, Department of PediatricsMichigan State University, Helen DeVos Children’s HospitalGrand RapidsUSA
  5. 5.Pediatric Critical Care Medicine, Department of PediatricsPenn State College of Medicine, Penn State Hershey Children’s HospitalHersheyUSA

Personalised recommendations